Who Paid My Doc
James Chappell
Denver, CO Medical Doctor
NPI 1598726440 CMS profile 208756
850 E Harvard Ave, Ste 405, Denver, CO 80210
General payments
$419,713
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, James Chappell of Denver, CO is reported in the CMS Open Payments database as having received $419,713 across 1,012 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $60,094 | 130 | |
| 2024 | General | $56,050 | 130 | |
| 2023 | General | $54,597 | 146 | |
| 2022 | General | $46,238 | 112 | |
| 2021 | General | $32,548 | 88 | |
| 2020 | General | $69,750 | 157 | |
| 2019 | General | $100,437 | 249 |
Beside peers
- James Chappell
- Colorado median
- Middle half of Colorado
- National median
In program year 2025, general payments to James Chappell were reported at $60,094. Among 17,059 Colorado profiles paid that year, the median was $144 and the middle half received between $41 and $532.
Show as a table
| Year | James Chappell | Colorado median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $100,437 | $137 | $40–$561 | $163 |
| 2020 | $69,750 | $109 | $32–$371 | $114 |
| 2021 | $32,548 | $127 | $33–$475 | $132 |
| 2022 | $46,238 | $136 | $40–$504 | $149 |
| 2023 | $54,597 | $144 | $43–$511 | $160 |
| 2024 | $56,050 | $144 | $42–$500 | $164 |
| 2025 | $60,094 | $144 | $41–$532 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 35 drugsPart D claims
2,186
Drug cost
$1,351,711
Branded share of claims
66.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | Brand | 419 | $632,439 | |
| Jardiance Empagliflozin | Brand | 258 | $334,769 | |
| Trulicity Dulaglutide | Brand | 86 | $118,871 | |
| Farxiga Dapagliflozin Propanediol | Brand | 56 | $82,419 | |
| Synjardy Empagliflozin/Metformin Hcl | Brand | 33 | $41,633 | |
| Ozempic Semaglutide | Brand | 15 | $41,034 | |
| Synthroid Levothyroxine Sodium | Brand | 271 | $26,688 | |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 41 | $18,104 | |
| Xigduo Xr Dapaglifloz Propaned/Metformin | Brand | 12 | $13,037 | |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 16 | $9,208 |
The 10 drugs with the highest cost, of 35 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,049 Part D prescribers listed as Specialist; they describe a distribution and say nothing about conduct.
Payments and prescribing
3 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| MOUNJARO |
|
$53,673 | 419 | — |
| SYNTHROID |
|
$25 | 271 | — |
| UNITHROID |
|
$13 | 17 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
1,012 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.